Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Repertoire is built around a technology dubbed Decode that’s designed to identify the components of the “immune synapse,” a type of junction ... Repertoire uses that information to uncover drugs for ...

Repertoire’s platform is designed to map the immune synapse, offering a comprehensive overview of ... Oxford BioTherapeutics to discover new antibody-based therapeutics for cancer. Roche also ...

Results: We identified distinct methylation patterns in immune synapse genes, differentiating tumors from adjacent normal tissues. Co-stimulatory genes such as CD40 were hypermethylated in tumors, ...

Characterizing an immune synapse between plasmacytoid dendritic cells and cancer cells that drives cancer cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research ...

Promising survival rates in KRAS-mutated non-small cell lung cancer were reported ... lung environment the T cell engager can create that immune synapse in small cell lung cancer and so I ...

Here the authors show, using knockout and tumor mouse models ... destroy target cells using a mechanically active cytolytic immune synapse. This Review examines the various ways in which ...

Here the authors show, using knockout and tumor mouse models ... destroy target cells using a mechanically active cytolytic immune synapse. This Review examines the various ways in which ...

Cambridge, USA-based biotech Repertoire Immune Medicines today ... maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune ...